News UpdateImportant Notice – Fraudulent Emails20 Oct 20210Patrys Ltd has been informed that fraudulent emails purporting to be sent from our Company are in circulation. The fraudulent…
ASX AnnouncementsQuarterly Activities Report and 4C Quarterly Cash Flow Report20 Oct 20210Patrys (ASX:PAB) has today published its Quarterly Activities Report and 4C Quarterly Cash Flow Report, for the quarter ended 30…
News UpdateAusBiotech Conference | Australia Biotech Invest & Partnering Conference19 Oct 20210Patrys CEO, Dr James Campbell, has composed some thoughts about his participation in AusBiotech’s upcoming events – the annual AusBiotech…
ASX AnnouncementsPatrys PATDX3 antibody drug conjugate significantly increases survival in animal model18 Oct 20210Patrys today released the latest data from its completed proof-of-concept study demonstrating the potential of its full-sized deoxymab antibody, PAT-DX3,…
ASX AnnouncementsPatrys AGM – 5th Nov 20215 Oct 20210The Patrys Ltd team is pleased to invite you to a virtual webinar for our Annual General Meeting (AGM): WHEN:…
MediaVideo Presentation | Proactive Lifesciences Webinar29 Sep 20210Patrys CEO and MD, Dr James Campbell, recently participated in a webinar hosted by Proactive to summarise Patrys’ key value…
News UpdateProactive Lifesciences Webinar, 28 September 202127 Sep 20210Join Patrys’ CEO and Managing Director Dr James Campbell at 12pm AEST on Tuesday 28 September 2021 for the Proactive…
News UpdateBioshares | September 202123 Sep 20210An update on Patrys has been published in the latest issue of investor newsletter Bioshares this week. Titled ‘Patrys Demonstrates…
VideoAusBiz | Dr James Campbell20 Sep 20210It was encouraging to see the market respond positively to Patrys’ (ASX:PAB) announcement of its preclinical study highlighting the potential…
ASX AnnouncementsPatrys demonstrates potential for deoxmabs in antibody drug conjugates (ADCs)15 Sep 20210Today Patrys announced new data from a successful preclinical study highlighting the potential for using our deoxymab antibodies as targeting…